Literature DB >> 15172039

Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.

Jeffry Bieber1, Arthur Kavanaugh.   

Abstract

Evidence supports the association of tuberculosis (TB) with tumor necrosis factor inhibitor therapy in patients who have rheumatoid arthritis. There seem to be differential risks of TB with the currently available inhibitors. Screening for latent TB infection with purified protein derivative is indicated for patients who are being considered for treatment; it seems to be effective in reducing the occurrence of TB in treated patients.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15172039     DOI： 10.1016/j.rdc.2004.01.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  10 in total

1.  Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis.

Authors:  S Agrawal; A Sharma
Journal:  Ann Rheum Dis       Date:  2007-02       Impact factor: 19.103

2.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.

Authors:  M H Schiff; G R Burmester; J D Kent; A L Pangan; H Kupper; S B Fitzpatrick; C Donovan
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

3.  T-SPOT.TB: an in vitro diagnostic assay measuring T-cell reaction to Mycobacterium tuberculosis-specific antigens.

Authors:  Antona J Wagstaff; Jean-Pierre Zellweger
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab.

Authors:  Alfonso Gutiérrez-Macías; Eva Lizarralde-Palacios; Pedro Martínez-Odriozola; Felipe Miguel-de la Villa
Journal:  Clin Rheumatol       Date:  2006-01-11       Impact factor: 2.980

5.  Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy.

Authors:  Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

Review 6.  Vasculitis induced by tumor necrosis factor-targeted therapies.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

7.  Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis.

Authors:  V S Gokul Krishnan; Sharath Madhyastha; Kusugodlu Ramamoorthi; Raviraj V Acharya; Vinaya Gopalaswamy
Journal:  J Pharmacol Pharmacother       Date:  2017 Jan-Mar

8.  Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls.

Authors:  Joo-Hyun Lee; Hae Sook Sohn; Jin Ho Chun; Hyoun-Ah Kim; Chang Hee Suh; Yun Woo Lee; Bo Young Yoon
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

9.  Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet's disease: A case report.

Authors:  Yan Shen; Hai-Fen Ma; Yan-Li Yang; Jian-Long Guan
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

10.  Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.

Authors:  Najat J Ziyadeh; Anja Geldhof; Wim Noël; Marijo Otero-Lobato; Suzan Esslinger; Soumya D Chakravarty; Yiting Wang; John D Seeger
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.